<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ADD8049D-3CA3-403E-907C-BCCAA6D666BC"><gtr:id>ADD8049D-3CA3-403E-907C-BCCAA6D666BC</gtr:id><gtr:firstName>Lars</gtr:firstName><gtr:surname>Fugger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137881016"><gtr:id>877F16BC-E1BD-4123-81D7-5AE844DDD780</gtr:id><gtr:title>Models for autoimmune disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137881016</gtr:grantReference><gtr:abstractText>Multiple sclerosis is a chronic disease that affects more than 1 in 1000 of the population. The cause of this disease is unknown and the disease process is only poorly understood. Only limited treatment can be offered today. To develop new treatments it is important to understand what is triggering the disease and how the disease unfolds. It is known that certain immune response genes, the MHC genes, predispose to the development of multiple sclerosis by participating in disease-causing immune responses, but it is unknown what is initiating these immune responses. Disease-associated MHC molecules can present small protein fragments derived from endogenous antigens to certain white blood cells (T cells) that subsequently attack the target organ. This programme focuses on how MHC molecules predispose to disease by combining functional and structural studies. This information will be important for the understanding of the disease and for the design of new drugs.</gtr:abstractText><gtr:technicalSummary>Having established the technology to generate mice expressing functional human transgenes of relevance for MHC associated autoimmune diseases we have developed animal models for multiple sclerosis. We will use these models to: (i) study which gene(s) confer primary susceptibility to multiple sclerosis and how other (secondary) disease associated genes interact with this primary gene(s) ; (ii) identify environmental factors that via e.g. molecular mimicry or unspecific inflammation contribute to disease development; (iii) test new therapeutic possibilities such small molecular inhibitory compounds, peptides, soluble MHC molecules and antibodies. In parallel with these functional studies we will study the structural basis for the MHC association in autoimmune diseases in collaboration with John Bell and Yvonne Jones. We will further study the structural basis for molecular mimicry with special emphasis on multiple sclerosis to understand how T cell cross reactivity may lead to autoimmune disease.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3095133</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>A 2.4 minutes animation of how a gene confers risk to multiple sclerosis</gtr:description><gtr:id>3C555208-BBB0-400B-9A30-5A7BE1497238</gtr:id><gtr:impact>Convey the message to professionals and laypersons in an understandable manner</gtr:impact><gtr:outcomeId>54621d04d27a96.16435248</gtr:outcomeId><gtr:title>How a gene confers risk to multiple sclerosis</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting with MS patients and their families</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6489BCF1-C081-4939-A430-FC0A78AB2DF4</gtr:id><gtr:impact>better understanding of MS and how it is being treated now and in the future

Positive feedback</gtr:impact><gtr:outcomeId>5462190704b804.16981161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV programme</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>610B1B96-D972-431A-BC65-CBACEC1077B4</gtr:id><gtr:impact>TV programme

Public awareness of our research</gtr:impact><gtr:outcomeId>35F027EF878</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Amiloride is a neuroprotective agent</gtr:description><gtr:grantRef>MC_U137881016</gtr:grantRef><gtr:id>F0A844FA-B208-40CD-A7B2-F91A5F01E2D8</gtr:id><gtr:impact>A clinical trial has been initiated</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>9C8ABB11FEA</gtr:outcomeId><gtr:patentId>US2010015127</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Amiloride as a neuroprotective agent</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Science Europe</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>7F1C2C27-17DD-4CD0-9EAC-96B55CDBD632</gtr:id><gtr:impact>Vivi section and access to big data</gtr:impact><gtr:outcomeId>54621a2737ffa3.45122168</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D706B827-88EF-4339-8DDE-68D3E7120A1F</gtr:id><gtr:title>Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7582aaffb949998b4e79f74f91a71a19"><gtr:id>7582aaffb949998b4e79f74f91a71a19</gtr:id><gtr:otherNames>Attfield KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_13706_26_22725951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DD702F6-31D7-455F-88F9-CEBD5ECBAD53</gtr:id><gtr:title>Dissection of the multiple sclerosis associated DR2 haplotype.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b46adfbb9a619dc3b1c361ec173f153"><gtr:id>7b46adfbb9a619dc3b1c361ec173f153</gtr:id><gtr:otherNames>Etzensperger R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>546215da509b71.65060985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67C3C7F9-7243-4C6B-9655-6A15590120A0</gtr:id><gtr:title>Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>546215dac07bb6.40085453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>577377E8-C2E2-48D8-8A2C-69F9BF405063</gtr:id><gtr:title>Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba5b17335e2433f6a3cc1adbc6b7ccc9"><gtr:id>ba5b17335e2433f6a3cc1adbc6b7ccc9</gtr:id><gtr:otherNames>Rigaud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13706_26_21543760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE6CBFA6-9B28-4F12-B50E-90DA040372F6</gtr:id><gtr:title>T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ed5289aaeeb07f31ea1141b71d9e736"><gtr:id>2ed5289aaeeb07f31ea1141b71d9e736</gtr:id><gtr:otherNames>Harkiolaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>546215db17ea89.50668196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F01C1D2-B55F-4A92-B909-39EAFB864908</gtr:id><gtr:title>Humanized mouse models for organ-specific autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>546215d9534542.02215968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>290F41F1-5A7D-4267-A103-3EA05A3C0216</gtr:id><gtr:title>Activation of central orexin/hypocretin neurons by dietary amino acids.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85ab7ae90ffc6693df7e319a7c636ef7"><gtr:id>85ab7ae90ffc6693df7e319a7c636ef7</gtr:id><gtr:otherNames>Karnani MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_13706_26_22099463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B13C6423-228D-45EC-90D0-EF1FDE7AA304</gtr:id><gtr:title>Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/850b9ea43c070c32110c02bbfd847b01"><gtr:id>850b9ea43c070c32110c02bbfd847b01</gtr:id><gtr:otherNames>Du Pr? MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_13706_26_21683079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E54FD3BB-F7AE-402A-9CE2-0D30E3313246</gtr:id><gtr:title>Pathogenic CD8(+) T cells in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>546215dbdedfc3.34486935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52932D07-9EFC-4EC9-A607-D474CC0038EF</gtr:id><gtr:title>Control of hypothalamic orexin neurons by acid and CO2.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2052982e09053c07158b4473ba838ee7"><gtr:id>2052982e09053c07158b4473ba838ee7</gtr:id><gtr:otherNames>Williams RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>9946F951481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>822B2ED8-49F7-464B-8791-2DC2B49EFB68</gtr:id><gtr:title>Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>546215d9d082c1.21242153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0029E6D0-15F7-4A9C-AA1C-0F953113B45D</gtr:id><gtr:title>Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbd5fc47723096b3e0f2a3c6fbdc73b2"><gtr:id>fbd5fc47723096b3e0f2a3c6fbdc73b2</gtr:id><gtr:otherNames>McMahon RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>pm_13706_26_21543847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2998AD48-7B83-4112-B6F5-1DB62C8A276C</gtr:id><gtr:title>Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dae4a004efebd5e873710e47bdf13ae"><gtr:id>9dae4a004efebd5e873710e47bdf13ae</gtr:id><gtr:otherNames>Arun T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13706_26_23365093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04D7C23B-0F4E-47D8-8D7B-59E13F607A8C</gtr:id><gtr:title>MHC class II proteins and disease: a structural perspective.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5e3a7dc78f1cd307cc16ee3d61ffa18"><gtr:id>d5e3a7dc78f1cd307cc16ee3d61ffa18</gtr:id><gtr:otherNames>Jones EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>D9972F407F2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDB6816A-33D7-43CE-8E90-237A66297EE2</gtr:id><gtr:title>Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71247b3e4da43217946b0d0e25e8029d"><gtr:id>71247b3e4da43217946b0d0e25e8029d</gtr:id><gtr:otherNames>Iversen AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>9DCAB21FA56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D45DC85-5DC0-4507-8FE7-2E75B7A2D5F5</gtr:id><gtr:title>Functional epistasis on a common MHC haplotype associated with multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aca7bd97ae25ab416a72d3d4333fabe"><gtr:id>1aca7bd97ae25ab416a72d3d4333fabe</gtr:id><gtr:otherNames>Gregersen JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>3713ACE76C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B39B33C-13AA-42E2-957B-6A2BBE843E7C</gtr:id><gtr:title>Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4770d673509c56c43b62f3b4d510bca7"><gtr:id>4770d673509c56c43b62f3b4d510bca7</gtr:id><gtr:otherNames>Kort JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>6EE1FD15096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72D94B66-106B-4B45-AB53-D8353858A86D</gtr:id><gtr:title>The value of animal models for drug development in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>4EC41A4988C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A3A07C9-C8B7-4910-AD7D-0C9C2ABD51FE</gtr:id><gtr:title>Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b8bbf8ceef749e0380e32360fcb3306"><gtr:id>9b8bbf8ceef749e0380e32360fcb3306</gtr:id><gtr:otherNames>Dzhambazov B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>1A22C1A3299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16D45912-A864-40B7-8B84-EE49319BBF90</gtr:id><gtr:title>Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9d97511c545be3ddf13697b09fbfedf"><gtr:id>e9d97511c545be3ddf13697b09fbfedf</gtr:id><gtr:otherNames>Tzartos JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>9737D802CF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>444E16BF-F47B-4AC0-9BCF-8991C2BDC961</gtr:id><gtr:title>From genes to function: the next challenge to understanding multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd30e9e606c194dffc5c461b84c98d6"><gtr:id>dfd30e9e606c194dffc5c461b84c98d6</gtr:id><gtr:otherNames>Fugger L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>546215db9277a4.13750880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B3E8EB1-EAAE-4C2B-94C2-B30FC94A27FA</gtr:id><gtr:title>Tandem-pore K+ channels mediate inhibition of orexin neurons by glucose.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ece16b8d922cfed620a6987d16a9d2"><gtr:id>59ece16b8d922cfed620a6987d16a9d2</gtr:id><gtr:otherNames>Burdakov D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>FDBB15800FF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84C667BB-5973-4784-AC2B-36D59985047D</gtr:id><gtr:title>Stimulation of orexin/hypocretin neurones by thyrotropin-releasing hormone.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b61316f7ce5315f0d5cb95096daa9507"><gtr:id>b61316f7ce5315f0d5cb95096daa9507</gtr:id><gtr:otherNames>Gonz?lez JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>DA71C97DA02</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137881016</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>